RU2628537C2 - Лечение нарушений свертываемости крови путем введения рекомбинантного фв - Google Patents

Лечение нарушений свертываемости крови путем введения рекомбинантного фв Download PDF

Info

Publication number
RU2628537C2
RU2628537C2 RU2014100107A RU2014100107A RU2628537C2 RU 2628537 C2 RU2628537 C2 RU 2628537C2 RU 2014100107 A RU2014100107 A RU 2014100107A RU 2014100107 A RU2014100107 A RU 2014100107A RU 2628537 C2 RU2628537 C2 RU 2628537C2
Authority
RU
Russia
Prior art keywords
var
fviii
rfv
patient
multimers
Prior art date
Application number
RU2014100107A
Other languages
English (en)
Russian (ru)
Other versions
RU2014100107A (ru
Inventor
Фридрих ШАЙФЛИНГЕР
Петер Турецек
Брюс ЭВЕНШТАЙН
Винг Йен ВОНГ
Тобиас М. СУИТЕР
Original Assignee
Баксалта Инкорпорейтед
Баксалта Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баксалта Инкорпорейтед, Баксалта Гмбх filed Critical Баксалта Инкорпорейтед
Publication of RU2014100107A publication Critical patent/RU2014100107A/ru
Application granted granted Critical
Publication of RU2628537C2 publication Critical patent/RU2628537C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2014100107A 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв RU2628537C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US61/495,884 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US61/511,901 2011-07-26
US201161523790P 2011-08-15 2011-08-15
US61/523,790 2011-08-15
PCT/US2012/041957 WO2012171031A1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017102679A Division RU2680402C2 (ru) 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв

Publications (2)

Publication Number Publication Date
RU2014100107A RU2014100107A (ru) 2015-07-20
RU2628537C2 true RU2628537C2 (ru) 2017-08-18

Family

ID=46321496

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014100107A RU2628537C2 (ru) 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв
RU2017102679A RU2680402C2 (ru) 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017102679A RU2680402C2 (ru) 2011-06-10 2012-06-11 Лечение нарушений свертываемости крови путем введения рекомбинантного фв

Country Status (23)

Country Link
US (3) US9272021B2 (enExample)
EP (3) EP3412305B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR101969515B1 (enExample)
CN (3) CN108210889A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3412305T3 (enExample)
ES (3) ES2976169T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL2717905T3 (enExample)
PT (3) PT3412305T (enExample)
RU (2) RU2628537C2 (enExample)
SG (2) SG10202002591QA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
CA3020346A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
KR102788331B1 (ko) 2017-07-07 2025-03-27 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료
EP4424366A3 (en) 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
EP3749696A1 (en) 2018-02-06 2020-12-16 Ablynx N.V. Methods of treating initial episode of ttp with immunoglobulin single variable domains
IL277464B1 (en) * 2018-03-21 2026-04-01 Baxalta Inc Separation of VWF and VWF propeptide using chromatographic methods
EA202192140A1 (ru) * 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
CN114929260A (zh) * 2019-09-11 2022-08-19 武田药品工业株式会社 与冯维勒布兰德因子和补体c1q的复合物相关的治疗方法
CN115335074A (zh) * 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
TW202237149A (zh) * 2020-11-24 2022-10-01 美商邦德治療公司 用於治療出血性障礙之組成物及方法
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
EP0218692A4 (en) 1985-04-11 1988-03-22 Childrens Medical Center VON WILLEBRAND FACTOR.
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
KR20100095441A (ko) 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
PL2291523T3 (pl) * 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
AU2010279463A1 (en) * 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FISCHER BE., Recombinant von Willebrand factor: potential therapeutic use.J Thromb Thrombolysis. 1999 Oct;8(3):197-205. MEULIEN P., et al., Processing and characterization of recombinant von Willebrand factor expressed in different cell types using a vaccinia virus vector.Thromb Haemost. 1992 Jan 23;67(1):154-60. FISCHER BE., et al., Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin.FEBS Lett. 1995 Nov 20;375(3):259-62. TURECEK PL., et al., Structure and function of a recombinant von Willebrand factor drug candidate.Semin Thromb Hemost. 2010 Jul;36(5):510-21. doi: 10.1055/s-0030-1255445. Epub 2010 Jul 15. RODEGHIERO F., et al., Treatment of von Willebrand disease.Semin Hematol. 2005 Jan;42(1):29-35. *

Also Published As

Publication number Publication date
PT2717905T (pt) 2018-07-02
KR20200091476A (ko) 2020-07-30
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
EP2717905A1 (en) 2014-04-16
AU2012267458A1 (en) 2014-01-09
AU2016202299B2 (en) 2017-07-20
LT2717905T (lt) 2018-10-10
JP2017019788A (ja) 2017-01-26
CA2838845A1 (en) 2012-12-13
AU2022201518A1 (en) 2022-03-24
EP3412305B1 (en) 2021-01-06
JP6347468B2 (ja) 2018-06-27
KR20190041032A (ko) 2019-04-19
RU2019103386A (ru) 2020-08-07
SG10202002591QA (en) 2020-05-28
US20120316116A1 (en) 2012-12-13
JP2019048892A (ja) 2019-03-28
DK2717905T3 (en) 2018-07-02
US20250387455A1 (en) 2025-12-25
PL3412305T3 (pl) 2021-05-31
AR086904A1 (es) 2014-01-29
ES2682249T3 (es) 2018-09-19
EP2717905B1 (en) 2018-05-23
AU2017206235A1 (en) 2017-08-03
SG10201604684WA (en) 2016-07-28
TR201808823T4 (tr) 2018-07-23
AU2016202299A1 (en) 2016-05-05
JP6527114B2 (ja) 2019-06-05
MX2020000083A (es) 2020-08-06
EP3858375B1 (en) 2024-03-20
AU2022201518B2 (en) 2025-07-03
PT3412305T (pt) 2021-01-29
DK3412305T3 (da) 2021-03-01
BR112013031795A2 (pt) 2016-12-20
HRP20180962T1 (hr) 2018-10-19
CA2838845C (en) 2019-08-06
CN103732244A (zh) 2014-04-16
RU2680402C2 (ru) 2019-02-21
ES2860450T3 (es) 2021-10-05
KR102319868B1 (ko) 2021-11-01
EP3858375A1 (en) 2021-08-04
MX350582B (es) 2017-09-11
US9272021B2 (en) 2016-03-01
US20160184403A1 (en) 2016-06-30
RU2014100107A (ru) 2015-07-20
AU2017206235B2 (en) 2019-10-17
MX2013014543A (es) 2014-06-11
SI2717905T1 (sl) 2018-09-28
PL2717905T3 (pl) 2018-10-31
DK3858375T3 (da) 2024-04-15
HUE039317T2 (hu) 2018-12-28
FI3858375T3 (fi) 2024-04-17
RU2017102679A (ru) 2018-12-19
CN107412743A (zh) 2017-12-01
RU2017102679A3 (enExample) 2018-12-19
JP2014516088A (ja) 2014-07-07
ES2976169T3 (es) 2024-07-24
EP3412305A1 (en) 2018-12-12
CN108210889A (zh) 2018-06-29
PT3858375T (pt) 2024-04-18
AU2020200026A1 (en) 2020-01-30
HK1257436A1 (zh) 2019-10-18
KR20140039285A (ko) 2014-04-01
NZ618790A (en) 2015-07-31
CN107412743B (zh) 2021-07-02
RU2019103386A3 (enExample) 2022-01-24
WO2012171031A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
US20250387455A1 (en) Treatment of coagulation disease by administration of recombinant vwf
US12016904B2 (en) Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
US20220168397A1 (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
RU2787855C2 (ru) Лечение нарушений свертываемости крови путем введения рекомбинантного фактора виллебранда
HK40056758A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40056758B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633A (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768A (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768B (en) Treatment of coagulation disease by administration of recombinant vwf
US20230398188A1 (en) Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
HK40115617A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40029176A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40029176B (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant
PC41 Official registration of the transfer of exclusive right

Effective date: 20211028